{"DataElement":{"publicId":"6433377","version":"1","preferredName":"Desensitization Method Performed Type","preferredDefinition":"A description of the desensitization method performed.","longName":"6433376v1.0:6433371v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6433376","version":"1","preferredName":"Desensitization Method Performed","preferredDefinition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Executed and carried through to completion.","longName":"6433374v1.0:2241241v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6433374","version":"1","preferredName":"Desensitization Method","preferredDefinition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"C155788:C71460","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desensitization","conceptCode":"C155788","definition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"763BFC45-7C47-131F-E053-F662850A6E2E","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241241","version":"1","preferredName":"Performed","preferredDefinition":"Performed; carried out.","longName":"C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-8839-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435033","version":"1","preferredName":"Techniques","preferredDefinition":"A practiced and regimented skill or series of actions.","longName":"C16847","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87DA-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"763BFC45-7C55-131F-E053-F662850A6E2E","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6433371","version":"1","preferredName":"Desensitization Method Type","preferredDefinition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Something distinguishable as an identifiable class based on common qualities.","longName":"6433371v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other method","valueDescription":"Other Method","ValueMeaning":{"publicId":"3288146","version":"1","preferredName":"Other Method","longName":"3288146","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE686AB8-616F-74D6-E040-BB89AD436198","latestVersionIndicator":"Yes","beginDate":"2011-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-721E-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Tacrolimus","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-7228-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"5127434","version":"1","preferredName":"Rituximab","longName":"5127434","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBA0-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-7232-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Plasmapheresis","valueDescription":"Plasmapheresis","ValueMeaning":{"publicId":"6159897","version":"1","preferredName":"Plasmapheresis","longName":"6159897","preferredDefinition":"The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8BE-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-723C-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Mycophenolate mofetil","valueDescription":"Mycophenolate Mofetil","ValueMeaning":{"publicId":"2567431","version":"1","preferredName":"Mycophenolate Mofetil","longName":"2567431","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D474-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-7250-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"IVIG","valueDescription":"Intravenous Immunoglobulin Therapy","ValueMeaning":{"publicId":"6051439","version":"1","preferredName":"Intravenous Immunoglobulin Therapy","longName":"6051439","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62E6E09D-AF1C-7E3A-E053-F662850A049D","latestVersionIndicator":"Yes","beginDate":"2018-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-16","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-725A-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Daratumumab","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-7264-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"763BEE7C-726E-6F0A-E053-F662850A124C","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6433370","version":"1","preferredName":"Desensitization Method Type","preferredDefinition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:Something distinguishable as an identifiable class based on common qualities.","longName":"C155788:C71460:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desensitization","conceptCode":"C155788","definition":"Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"763BEE7C-71F7-6F0A-E053-F662850A124C","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"ONEDATA","dateModified":"2018-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"763BEE7C-7208-6F0A-E053-F662850A124C","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"base_desen_meth_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the desensitization","type":"Preferred Question Text","description":"What was the desensitization method performed?","url":null,"context":"NHLBI"},{"name":"Method of desensitization","type":"Alternate Question Text","description":"Method of desensitization","url":null,"context":"NHLBI"},{"name":"Method of desensitization","type":"Application Standard Question Text","description":"Method of desensitization","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"763C0EF5-F1C2-4ACB-E053-F662850ABB69","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-19","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}